Latest News

NovaBiotics Chief Scientific Officer and Founder of the leading clinical-stage biotechnology company, Dr Deborah O'Neil, will be presenting at the biotechnology industry's largest event, the BIO International Convention in Washington, 27-30 June, giving an update on the technology and recent developments as well as outlining the Company's future plans.

Dr O'Neil will be presenting on Thursday, June 30 at 9.30am in the Capitol Hill suite.

The company is preparing to carry out a multi-centre phase IIb clinical study ("the study") for its' lead asset Novexatin® in 2011/2012 in the USA. Partnering discussions are ongoing in parallel with potential licensing partners.

Novexatin®, the company’s lead product, is a topical treatment for fungal nail infection and addresses a poorly served $3 billion global market. Novexatin® is a unique product, with clinical data derived thus far confirming that it addresses the profound safety and efficacy shortcomings of existing remedies for fungal nail infection. NovaBiotics’ data suggest a step change in patient care is possible with superior cure rates predicted by the IIb study following a month’s treatment rather than the 12 months required for current topical therapies.

Dr Deborah O’Neil and Professor Andy Porter will attend the event as part of the Scottish delegation. Dr Deborah O’Neil commented, “I am delighted that NovaBiotics has been selected to present at this year’s BIO International in Washington and that we’ll be able showcase our technology to a worldwide audience. This comes on top of an already packed partnering schedule through which we're looking forward to sharing recent exciting advances with Novexatin®, Lynovex™, Novamycin® and Novarifyn™ with existing and also new potential partners.

"Our discussions with the US Food and Drug Administration (FDA) are on track towards gaining investigational new drug (IND) approval for Novexatin® to facilitate a large, multi-centre phase IIb efficacy study, which will be a major milestone in this potentially world-beating technology's commercialisation journey."

Professor Andy Porter adds, "I am thrilled with the continued success of Novexatin but also have high hopes for our pipeline products which include Lynovex™ our dual muco-active anti-bacterial already showing exciting activity when compared with similar molecules, and Luminaderm® our OTC platform from which compounds are currently being assessed by some of the world’s largest consumer health players."